Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508312-39-00

Acronym

AB-101-001

Enrollment

Registered

2024-12-04

Start date

2024-12-13

Completion date

2025-11-25

Last updated

2025-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B virus Infection

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Bulgaria, Italy, Romania

None listed

Source: EU CTIS · Data processed: Feb 4, 2026